Summary
CME Group Inc. (CME) filed an 8-K on April 28, 2005, reporting an amendment to its existing License Agreement with The Nasdaq Stock Market, Inc. (Nasdaq). This amendment is significant for investors as it extends the exclusive license term from October 9, 2011, to October 9, 2012. This extension provides CME with continued operational certainty and revenue streams related to the licensed Nasdaq intellectual property for an additional year.
Key Highlights
- 1CME Group Inc. amended its License Agreement with The Nasdaq Stock Market, Inc.
- 2The amendment extends the exclusive license term by one year, from October 9, 2011, to October 9, 2012.
- 3The agreement now includes a license for the Nasdaq Biotechnology Index.
- 4This expanded license allows CME to trade futures and options on futures based on the Nasdaq Biotechnology Index.
- 5The filing indicates that the full amendment document will be provided in CME's Form 10-Q for the quarter ended June 30, 2005.
- 6The event date for this amendment was April 25, 2005.